<unk>  by mouth is used for the treatment of serious infections caused by susceptible strains of Candida or Cryptococcus neoformans. It can also be used for the treatment of chromomycosis (chromoblastomycosis), if susceptible strains cause the infection.<unk>  must not be used as a sole agent in life-threatening fungal infections due to relatively weak antifungal effects and fast development of resistance, but rather in combination with amphotericin B and/or azole antifungals such as fluconazole or itraconazole. Minor infections such as candidal cystitis may be treated with<unk>  alone. In some countries, treatment with slow intravenous infusions for no more than a week is also a therapeutic option, particular if the disease is life-threatening. Serious fungal infections may occur in those who are immunocompromised. These people benefit from combination therapy including<unk> , but the incidence of side-effects of a combination therapy, particular with amphotericin B, may be higher. Pregnancy and breastfeeding In animal models (rats),<unk>  has been found to be teratogenic. Sufficient human data does not exist. Pregnant women should be given<unk>  only if the potential benefits exceed the potential harm to the fetus. It is not known if<unk>  is distributed in human breast milk. Given the potential risk to the child, the patient should not breastfeed during treatment with<unk> . Children The efficacy and safety in patients under 18 years of age has not been determined.
Flucytosine
Micafungin
Caspofungin
Miconazole
Fluconazole
Fosravuconazole
Anidulafungin
Ganciclovir